Karyopharm Therapeutics, Inc. KPTI 深 滬
等待開盤 06-26 09:30:00 美东时间
9.34
+0.220
+2.41%
華盛通- 最 高9.65
- 今 開9.08
- 成交量 20.63万股
- 最 低 9.01
- 昨 收 9.12
- 總市值 2.12亿
- 52周最高 10.99
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 3.6503
- 委 比 88.30%
- 總股本 2266.29万
- 歷史最高 735.075
- 量 比 0.72
- 振 幅 7.02%
- 歷史最低 5.00
- 每 手 1
- 風險率 1.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics announced the appointment of Barry Greene to its Board of Directors. With over three decades of experience in the biopharmaceutical industry, Greene brings a proven track record of building and scaling innovative companies across rare diseases, neuroscience, and oncology. His leadership includes roles at Sage Therapeutics and Alnylam Pharmaceuticals, where he contributed to the development and commercialization of novel therapie...
06-22 20:10
Karyopharm posts Phase 3 SENTRY trial presentation on selinexor plus ruxolitinib in myelofibrosis
Karyopharm posts Phase 3 SENTRY trial presentation on selinexor plus ruxolitinib in myelofibrosis Karyopharm published Phase 3 SENTRY trial results evaluating selinexor with ruxolitinib in JAK inhibitor-naïve myelofibrosis. Combination delivered rapid, deeper, sustained spleen volume reduction versu
06-14 16:14
Karyopharm将邀专家解读骨髓纤维化III期SENTRY试验结果
Karyopharm Therapeutics Inc．今日宣布，将于美国东部时间6月2日下午2：00召开投资者电话会议，详细解读selinexor联合r...
06-01 22:44
Karyopharm Expands Equity Incentives and Launches PSU Program
An update from Karyopharm Therapeutics ( ($KPTI) ) is now available. At its May...
05-29 04:27
Karyopharm management participates in Jefferies Global Healthcare Conference fireside chat
Karyopharm management participates in Jefferies Global Healthcare Conference fireside chat Karyopharm will take part in the 2026 Jefferies Global Healthcare Conference on June 4, 2026. Senior management is scheduled for a fireside chat at 8:10 a.m. ET in New York. Disclaimer: This news brief was cre
05-28 19:31
Karyopharm Therapeutics shares are trading lower. The company reported its Q1 financial results.
Karyopharm Therapeutics shares are trading lower. The company reported its Q1 f...
05-15 23:52
Karyopharm Earnings Call: Trial Wins, Cash Questions
Karyopharm Therapeutics INC (($KPTI)) has held its Q1 earnings call. Read on fo...
05-15 08:20
Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
Karyopharm Therapeutics (NASDAQ:KPTI) released first-quarter financial results ...
05-14 21:37
Karyopharm Q1 FY26 operating loss narrows 20% to $26.76 million; revenue rises 17% to $35.07 million
Karyopharm Q1 FY26 operating loss narrows 20% to $26.76 million; revenue rises 17% to $35.07 million Karyopharm Therapeutics posted Q1 net loss of USD 22.39 million, narrowing 5% from year-ago period, as revenue rose 17% to USD 35.07 million. Operating loss improved 20% to USD 26.76 million, while p
05-14 19:47
Karyopharm Q1 net loss narrows
Karyopharm Q1 net loss narrows Overview U.S. cancer therapy maker's net loss for Q1 narrowed, reflecting improved operating efficiency and disciplined cost management Outlook Karyopharm reaffirms 2026 total revenue guidance of $130 mln to $150 mln Result Drivers GROSS-TO-NET ADJUSTMENTS - Higher net
05-14 19:42
